27 articles
Immunotherapy shrinks brain melanoma tumors in roughly half of selected patients, but steroids must be tapered and the brain stabilized before treatment.
Insurance coverage mandates boost dense breast supplemental screening nearly four times more than notification laws alone, a study of 12.6 million women.
The FDA approved Tudriqev for melanoma patients who've failed immunotherapy, offering a 24.2% response rate where few second-line options existed.
CAR-T cell therapy fails in over half of responders, but new gene editing and multi-target designs may finally change that for solid tumor patients.
The HPV vaccine cuts head and neck cancer risk by 68% in young recipients, new research shows, offering far broader protection than cervical cancer alone.
A personalized melanoma vaccine combined with KEYTRUDA cut recurrence risk in a landmark Phase 3 trial, marking the first mRNA cancer therapy to beat.
A new cancer vaccine called PROTEXI repurposes COVID-19 immune memory to attack tumors, slowing growth and boosting survival in melanoma and breast cancer.
Blood tests could soon predict which melanoma patients benefit from immunotherapy, after researchers identified immune cell patterns linked to survival.
A single blood test could screen for multiple cancers at once, including pancreatic and ovarian, and UNC is recruiting 2,000 North Carolinians to study it.
A new immunotherapy combo cut death risk by 52% in advanced lung cancer patients who stopped responding to checkpoint inhibitors, offering a promising new.
Women with BRCA mutations or strong family history need high-risk breast cancer screening twice yearly, alternating MRI and mammogram, starting at age 30.
Your genes may predict CAR-T cell therapy success: researchers linked three key variants to toxicity risk and treatment effectiveness in 200+ lymphoma.
Harvard's COMPASS AI predicts cancer immunotherapy response with 8.5% greater accuracy, helping doctors identify which patients will truly benefit before.
A Johns Hopkins vaccine targeting KRAS mutations triggered immune responses in 90% of high-risk patients, and none developed pancreatic cancer during.
AI-powered handheld devices have screened over 33,000 women for breast and cervical cancer in rural India, reaching villages without mammography machines.
A new melanoma drug combo shows 58% better progression-free survival; here's what advanced melanoma patients should know before their next oncology visit.
New cervical cancer screening guidelines prioritize HPV testing every three years for average-risk women ages 30 to 65, reducing unnecessary procedures.
Vaginal and vulvar cancers have survival rates as low as 53%, yet no standardized screening guidelines exist to catch them early.
Prostate cancer screening talks happen in under 7% of visits, yet men who have them are twice as likely to get screened, a new study finds.
New research finds 1 in 4 prostate cancer patients show tumor growth on scans despite stable PSA levels, suggesting imaging must join PSA testing.
Engineered bacterial vesicles injected into tumors activated whole-body immune responses against melanoma, colon, and breast cancer, offering a safer.
Colorectal cancer rates in adults under 50 have risen 63% since 1988; a new blood test could screen patients as young as 18.
A large NHS study found a multi-cancer blood test missed its main goal, yet still caught 16% more early-stage cancers and cut emergency diagnoses by 25%.
A new colorectal cancer drug combination improved survival to 10.9 months versus 9.4, but showed no significant benefit for patients without liver.
Personalized melanoma vaccines paired with immunotherapy are pushing survival rates from below 10% to nearly 40%, but equitable access remains a critical.
Breast cancer survivors face 17% higher cancer risk, but a new study finds annual multicancer blood tests could prevent hundreds of late-stage diagnoses.
Scientists found that blocking a protein called DHHC3 in melanoma cells triggers a powerful immune attack, shrinking tumors in animal models.
